Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors

PURPOSE: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity. EXPERIMENTAL DESIGN: Patients with refractory advanced soli...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Diamond, Jennifer R., Bastos, Bruno R., Hansen, Ryan J., Gustafson, Daniel L., Eckhardt, S. Gail, Kwak, Eunice L., Pandya, Shuchi S., Fletcher, Graham C., Pitts, Todd M., Kulikowski, Gillian N., Morrow, Mark, Arnott, Jamie, Bray, Mark R., Sidor, Carolyn, Messersmith, Wells, Shapiro, Geoffrey I.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2010
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3867298/
https://ncbi.nlm.nih.gov/pubmed/21131552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2144
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन